Get started

Vaccine

Novavax (NVAX) - Vaccine Testing - SARS, MERS, SARS-CoV-2 (2019)This is an interesting idea based on outbreaks of SARS, MERS, and SARS-CoV-2 (2019). Novavax successfully created vaccines for SARS, MERS, and are on track to create one for SARS-CoV-2 (2019) - ir.novavax.com Vaccine in development for SARS-CoV-2 (2019): seekingalpha.com Is this a good investment? If the vaccination is successful and/or coronavirus outbreak continues, it could trend upwards significantly. Disclaimer: This is not financial advice. Just my own opinion based on research. Important Notes: For your own safety, the CDC recommends you WASH YOUR HANDS FREQUENTLY. COVER YOUR MOUTHS WHEN YOU COUGH/SNEEZE.
NASDAQ:NVAXLong
by traderman001
2
American cancer vaccine patent boost $PCIB.OL over falling wedgePCI Biotech: US patent granted for the vaccine technology (fimaVACC) in combination with cytokines Oslo (Norway), 21 January 2020 – PCI Biotech OSL:PCIB , a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has granted the company a US patent covering the use of fimaVacc in combination with cytokines. Cytokines are small proteins that are involved in cell signaling, and that are very important in the immune system, modulating both cell-based and humoral immune responses. The combination of cytokines with PCI Biotech’s vaccine technology, fimaVacc, has been shown to be effective for enhancing cellular immune responses that are important for the effect of therapeutic vaccines. The now granted US patent gives broad coverage for the combination of various cytokines with the fimaVacc technology. There are many vaccines under development utilising cytokines to elicit immune responses. The US patent granted today is important for PCI Biotech’s development strategy, as it supplements our ability to generate an internal future vaccine pipeline, in addition to bringing value for the fimaVacc technology in partnering efforts, said Per Walday, CEO of PCI Biotech. As part of PCI Biotech’s strategy for applying the PCI-technology for therapeutic cancer vaccines, several global patent applications were filed in 2013 and 2014. Today’s granted US patent secure protection until 2035 and this patent application is still pending in Europe and key Asian markets. Press release direct URL: pcibiotech.no
OSL:PCIB
by savepiginvest
$PCIB.OL: Successful clinical translation of fimaVacc technologyOSL:PCIB www.netfonds.no Oslo (Norway), 2 May 2019 . PCI Biotech ( OSL:PCIB ), a cancer focused clinical-stage company developing innovative therapeutics that address significant unmet medical needs today announced that the final immune response results from the fima_Vacc_ Phase I study in healthy volunteers indicate a clear enhancement of both CD8 and CD4 T-cell responses and an improved CD8 T-cell functionality after vaccination at tolerable dose levels. The interim clinical results previously reported that fima_Vacc_ may enhance overall T-cell responses, especially to the HPV peptide, which is much less immunogenic than the KLH protein. The final data confirms these results, showing a substantial increase in number of T-cell responders to the HPV peptides already after two vaccinations and a clear enhancement in the T-cell responses compared to the control group. The important CD8 responses are also more robust with fima_Vacc_ and exhibit increased functionality compared to control. The overall clinical data cover more than 90 subjects providing clinical support of fima_Vacc_.s potential to enhance the cellular immune responses that are important for therapeutic effect of vaccines. This enhancement of cellular immune responses was seen at well tolerated fima_Vacc_ dose levels, with the tolerability of fima_Vacc_ also established across a wide range of doses. The analysis of overall T-cell responses has been done in collaboration with Oslo University Hospital, The Radium Hospital, while the analysis of CD8 T-cell responses has been done at Leiden University Medical Centre (LUMC). Per Walday, CEO of PCI Biotech, said_: “Improving immunogenicity of vaccine candidates is a main priority in the immunotherapy industry. The encouraging results of the Phase I study provide proof of concept and efficacy in terms of optimal dosing of fimaVacc in humans as well as an overall characterization of tolerability, in keeping with the target objectives of the trial and paving the way for further development in a clinical setting.”_ The study was designed as an open-label, antigen-adjuvant controlled study with the objectives to determine immune responses, safety and tolerability of fima_Vacc_ in healthy volunteers. The study was performed with two model vaccines; a large immunogenic protein (KLH) and two smaller less immunogenic peptides (HPV). More than 90 subjects are included and recruitment is now stopped.
OSL:PCIBLong
by savepiginvest
1